Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds
Tóm tắt
Từ khóa
Tài liệu tham khảo
Dibra, 2007, Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis: meta-analysis of randomized trials, J Am Coll Cardiol, 49, 616, 10.1016/j.jacc.2006.10.049
Joner, 2006, Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk, J Am Coll Cardiol, 48, 193, 10.1016/j.jacc.2006.03.042
Kedhi, 2010, Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial, Lancet, 375, 201, 10.1016/S0140-6736(09)62127-9
Park, 2011, Everolimus-eluting versus sirolimus-eluting stents in patients undergoing percutaneous coronary intervention: the EXCELLENT (Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting) randomized trial, J Am Coll Cardiol, 58, 1844, 10.1016/j.jacc.2011.07.031
Stone, 2010, Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease, N Engl J Med, 362, 1663, 10.1056/NEJMoa0910496
Byrne, 2011, Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial, J Am Coll Cardiol, 58, 1325, 10.1016/j.jacc.2011.06.027
Raber, 2011, Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization, J Am Coll Cardiol, 57, 2143, 10.1016/j.jacc.2011.01.023
Chevalier, 2009, Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberte paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial—phase 2, Circ Cardiovasc Interv, 2, 188, 10.1161/CIRCINTERVENTIONS.108.823443
Stefanini, 2011, Long-term clinical outcomes of biodegradable polymer Biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial, Lancet, 378, 1940, 10.1016/S0140-6736(11)61672-3
Smits, 2013, Abluminal biodegradable polymer Biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial, Lancet, 381, 651, 10.1016/S0140-6736(12)61852-2
Puricel, 2013, Long-term comparison of everolimus-eluting and Biolimus-eluting stents, EuroIntervention, 9, 336, 10.4244/EIJV9I3A55
Natsuaki, 2013, Biodegradable polymer Biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial, J Am Coll Cardiol, 62, 181, 10.1016/j.jacc.2013.04.045
Ormiston, 2008, A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet, 371, 899, 10.1016/S0140-6736(08)60415-8
Serruys, 2009, A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods, Lancet, 373, 897, 10.1016/S0140-6736(09)60325-1
Okamura, 2010, In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial, EuroIntervention, 5, 932, 10.4244/EIJV5I8A157
Moreno, 2007, Clinical impact of in-stent late loss after drug-eluting coronary stent implantation, Eur Heart J, 28, 1583, 10.1093/eurheartj/ehl423
Mauri, 2005, Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison, Circulation, 111, 3435, 10.1161/CIRCULATIONAHA.104.513952
Arroyo, 2014, Comparison of everolimus-eluting and Biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial, Trials, 15, 9, 10.1186/1745-6215-15-9
Otsuka, 2014, Long-term safety of an everolimus-eluting bioresorbable vascular scaffold and the cobalt-chromium XIENCE V stent in a porcine coronary artery model, Circ Cardiovasc Interv, 7, 330, 10.1161/CIRCINTERVENTIONS.113.000990
Serruys, 2010, Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes, Circulation, 122, 2301, 10.1161/CIRCULATIONAHA.110.970772
Cutlip, 2007, Clinical end points in coronary stent trials: a case for standardized definitions, Circulation, 115, 2344, 10.1161/CIRCULATIONAHA.106.685313
Thygesen, 2012, Third universal definition of myocardial infarction, J Am Coll Cardiol, 60, 1581, 10.1016/j.jacc.2012.08.001
Mauri, 2005, Robustness of late lumen loss in discriminating drug-eluting stents across variable observational and randomized trials, Circulation, 112, 2833, 10.1161/CIRCULATIONAHA105.570093
Prabhu, 2007, Modeling of degradation and drug release from a biodegradable stent coating, J Biomed Mater Res A, 80, 732, 10.1002/jbm.a.31053
Chevalier, 2013, First report of the four year clinical results of the ABSORB trial evaluating the Absorb everolimus eluting bioresorbable vascular scaffold in the treatment of patients with de novo coronary artery lesions, J Am Coll Cardiol, 62, B11, 10.1016/j.jacc.2013.08.762
Whitbourn, 2013, ABSORB EXTEND: an interim report on the 24-month clinical outcomes from the first 250 patients enrolled, J Am Coll Cardiol, 62, B11, 10.1016/j.jacc.2013.08.761
Onuma, 2011, Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?, Circulation, 123, 779, 10.1161/CIRCULATIONAHA.110.971606
Capodanno, 2014, Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry, EuroIntervention